Challenges and Strategies in Drug Delivery Systems for Treatment of Pulmonary Infections.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Nichols, Brittany L B
Edgar, Kevin J
MetadataShow full item record
AbstractInhalation therapy has been reported as the most effective treatment for respiratory bacterial infections due to the increasing relevance of drug bioavailability. Drug delivery systems (DDS) have the capacity to overcome pulmonary biological barriers limiting the bioavailability of inhaled anti-infectives. This is important to eradicate bacterial infections and to prevent the development of bacterial resistance. Despite substantial efforts in the field, the current state-of-the-art often fails to achieve those goals, and we still observe increasing bacterial resistance. We give a brief insight on benefits and challenges in pulmonary delivery of anti-infectives. In the context of drug delivery development for pulmonary infections, particularly focusing on Pseudomonas aeruginosa (PA) infections, this mini review will critically discuss the main requirements, as well as the recent strategies of drug delivery system synthesis and preparation. Finally, interaction of DDS with crucial pulmonary biological barriers will be of great importance for the success of future applications of the developed DDS.
CitationEur J Pharm Biopharm. 2019 Sep 4. pii: S0939-6411(19)30620-4. doi: 10.1016/j.ejpb.2019.09.002.
AffiliationHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors.
- Authors: Nafee N, Husari A, Maurer CK, Lu C, de Rossi C, Steinbach A, Hartmann RW, Lehr CM, Schneider M
- Issue date: 2014 Oct 28
- Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis--where do we stand?
- Authors: Klinger-Strobel M, Lautenschläger C, Fischer D, Mainz JG, Bruns T, Tuchscherr L, Pletz MW, Makarewicz O
- Issue date: 2015 Aug
- Current State of Nanomedicines in the Treatment of Topical Infectious Disorders.
- Authors: Thakur K, Sharma G, Singh B, Chhibber S, Katare OP
- Issue date: 2018
- Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
- Authors: Greally P, Whitaker P, Peckham D
- Issue date: 2012 Jun
- Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
- Authors: Langton Hewer SC, Smyth AR
- Issue date: 2017 Apr 25